Shilpa Medicare gets DCGI approval for ‘2-Deoxy2-Glucose’

31 Aug 2021 Evaluate

Shilpa Medicare has received Drugs Controller General of India (DCGI) approval for ‘2-Deoxy2-Glucose’ (Bulk & Oral Powder). The bulk is manufactured by Shilpa Medicare, API facility in Raichur,' Karnataka. The Oral Powder is manufactured by its subsidiary, Shilpa Therapeutics, facility in Hyderabad, Telangana. 2-Deoxy-2-Glucose Oral Powder is approved for the treatment of adjunct therapy in moderate to severe COVID-19 patients. The product will be available with a brand name '2-DGSHIL'.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

300.20 13.00 (4.53%)
03-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1702.80
Dr. Reddys Lab 1235.00
Cipla 1322.45
Zydus Lifesciences 902.95
Lupin 2186.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×